Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Exclusion Criteria

• •Current clinically significant psychiatric disease.
• •Evidence of structural abnormalities such as major stroke or mass on MRI that would have made a diagnosis of impairment due to AD unlikely or was likely to interfere with interpretation of a PET scan on MRI.
• •Claustrophobic or otherwise unable to tolerate the imaging procedure.
• •Current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram (including, but not limited to, corrected QT interval \>450 msec).
• •Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
• •History of alcohol abuse or substance abuse or dependence
• •Female subjects of childbearing potential who were not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.
• •Required medications with a narrow therapeutic window
• •Received a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to imaging session
• •Receiving any investigational medications or had participated in a trial with investigational medications within the last 30 days